



## **bioMérieux Showcases Myla™ at ASM 2010: New Informatics Solution to Transform the Microbiology Laboratory**

### ***Innovative solution optimizes laboratory workflow and clinical information management***

*Marcy l'Etoile, France – May 25, 2010* — A world leader in *in vitro* diagnostics, bioMérieux presented Myla™, a revolutionary new middleware solution to improve connectivity, laboratory workflow and information management, at the 110<sup>th</sup> General Meeting of the American Society for Microbiology (ASM) in San Diego. Part of bioMérieux's FMLA™\* solutions and services, Myla is an intelligent browser-based application that consolidates and manages microbiology data generated from a variety of sources and converts these data into actionable information for treatment decisions. Designed to transform the way that laboratory managers and technicians work, Myla recaptures time spent on information retrieval and reporting activities through a simple dashboard-based user interface that provides full control of lab workflow.

"Myla brings two key benefits to the microbiology lab: significantly improving operational efficiency and making the most relevant information readily available to clinicians so they can take action rapidly," said Stéphane Bancel, Chief Executive Officer of bioMérieux. "Time to treatment makes a critical difference in patient outcomes and Myla is a fundamental part of bioMérieux's Full Microbiology Lab Automation to deliver faster results."

Laboratory consolidation and healthcare budget constraints have placed heightened demands on laboratory managers. They are faced with greater demand for quality assurance and traceability of samples and results. Lab managers must handle an increasingly complex workflow with a smaller workforce and, in many cases, fewer skilled technicians. There is also a strong drive to build more efficiency into daily operations by minimizing the time and cost to process samples and generate results. As the world leader in microbiology diagnostics, bioMérieux developed Myla in response to these needs.

Limited launch of Myla is planned for June, to be followed by a full launch in the fourth quarter of 2010.

### **About Myla**

The Myla software solution will offer:

- Rich connectivity between bioMérieux instruments, other instruments, the laboratory information system and eventually, other hospital information systems. It will also enable faster time to results with real-time collection, consolidation and delivery of clinically relevant test results.
- Improved information management between automated systems that will eliminate redundant data entry, saving time and minimizing potential errors. Myla will include a dashboard for laboratory managers and technicians, which provides a comprehensive view of all testing activities in the lab. It will thus be possible to adjust resources to anticipate

bottlenecks and improve efficiency. The software will also send real-time alerts for critical lab information, for example increasing bacterial resistance trends, so that hospitals can immediately implement specific prevention and control actions.

- Enhanced visibility to manage workflow. Laboratory managers will have the flexibility to customize their dashboard to show information such as quality indicators and workflow metrics for continuous operational improvement. Myla will be web enabled, making the software easy to deploy and facilitating access to information from multiple remote sites.

Follow Myla on Twitter for the latest news and updates: <http://twitter.com/mylahelps>

For more information, visit: [www.mylahelps.com](http://www.mylahelps.com)

#### **\*About FMLA™**

Full Microbiology Lab Automation (FMLA) helps customers achieve substantial productivity gains by improving lab efficiency and utilization of automated systems. Focused on faster time to result for improved patient care, bioMérieux introduced FMLA in 2008 to streamline the workflow and efficiency of the microbiology laboratory, from sample reception and distribution, organism identification and antimicrobial resistance analysis, to result management and interpretation.

For more information, visit: [www.biomerieux-diagnostics.com/fmla](http://www.biomerieux-diagnostics.com/fmla)

#### **About bioMérieux**

##### ***Advancing diagnostics to improve public health***

A world leader in the field of *in vitro* diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2009, revenues reached €1.223 billion with 85% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at [www.biomerieux.com](http://www.biomerieux.com)

#### **Contacts**

##### ***Investor Relations***

###### **bioMérieux**

Isabelle Tongio

Tel: + 33 4 78 87 22 37

[investor.relations@eu.biomerieux.com](mailto:investor.relations@eu.biomerieux.com)

##### ***Media Relations***

###### **bioMérieux**

Koren Wolman-Tardy

Tel: + 33 4 78 87 20 08

[media@eu.biomerieux.com](mailto:media@eu.biomerieux.com)

###### **Fleishman-Hillard**

Kimberly Mays

Tel: + 1 216-928-3459

[kimberly.mays@fleishman.com](mailto:kimberly.mays@fleishman.com)

###### **Image Sept**

Tiphaine Hecketsweiler

Tel: + 33 1 53 70 74 59

[thecketsweiler@image7.fr](mailto:thecketsweiler@image7.fr)